Controversies in clinical cancer dormancy

Jonathan W. Uhr, Klaus Pantel

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Clinical cancer dormancy is defined as an unusually long time between removal of the primary tumor and subsequent relapse in a patient who has been clinically disease-free. The condition is frequently observed in certain carcinomas (e.g., breast cancer), B-cell lymphoma, and melanoma, with relapse occurring 5-25 y later. Clinical data suggest that a majority of breast cancer survivors have cancer cells for decades but can remain clinically cancer-free for their lifetime. Thus, there is a major effort to characterize the molecular mechanisms responsible for inducing tumor cell dormancy using experimental models or studying the early phases of cancer growth in humans. Many molecules and signaling pathways have been characterized and have led to concepts that dominate the field, such as the possible role of innate and adaptive immunity in immune surveillance and initiation and maintenance of dormancy. However, recent clinical data do not support many of these concepts. Several areas need further study to determine their relevance to clinical cancer dormancy. We suggest hypotheses that may contribute to elucidation of the mechanisms underlying the dormant state.

Original languageEnglish (US)
Pages (from-to)12396-12400
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume108
Issue number30
DOIs
StatePublished - Jul 26 2011

Fingerprint

Neoplasms
Breast Neoplasms
Recurrence
B-Cell Lymphoma
Adaptive Immunity
Innate Immunity
Survivors
Melanoma
Theoretical Models
Maintenance
Carcinoma
Growth

Keywords

  • Chronic cancer
  • Circulating tumor cell
  • Organ size control

ASJC Scopus subject areas

  • General

Cite this

Controversies in clinical cancer dormancy. / Uhr, Jonathan W.; Pantel, Klaus.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 108, No. 30, 26.07.2011, p. 12396-12400.

Research output: Contribution to journalArticle

Uhr, Jonathan W. ; Pantel, Klaus. / Controversies in clinical cancer dormancy. In: Proceedings of the National Academy of Sciences of the United States of America. 2011 ; Vol. 108, No. 30. pp. 12396-12400.
@article{b7b3648e304b4782ac7c4d27f7732a70,
title = "Controversies in clinical cancer dormancy",
abstract = "Clinical cancer dormancy is defined as an unusually long time between removal of the primary tumor and subsequent relapse in a patient who has been clinically disease-free. The condition is frequently observed in certain carcinomas (e.g., breast cancer), B-cell lymphoma, and melanoma, with relapse occurring 5-25 y later. Clinical data suggest that a majority of breast cancer survivors have cancer cells for decades but can remain clinically cancer-free for their lifetime. Thus, there is a major effort to characterize the molecular mechanisms responsible for inducing tumor cell dormancy using experimental models or studying the early phases of cancer growth in humans. Many molecules and signaling pathways have been characterized and have led to concepts that dominate the field, such as the possible role of innate and adaptive immunity in immune surveillance and initiation and maintenance of dormancy. However, recent clinical data do not support many of these concepts. Several areas need further study to determine their relevance to clinical cancer dormancy. We suggest hypotheses that may contribute to elucidation of the mechanisms underlying the dormant state.",
keywords = "Chronic cancer, Circulating tumor cell, Organ size control",
author = "Uhr, {Jonathan W.} and Klaus Pantel",
year = "2011",
month = "7",
day = "26",
doi = "10.1073/pnas.1106613108",
language = "English (US)",
volume = "108",
pages = "12396--12400",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "30",

}

TY - JOUR

T1 - Controversies in clinical cancer dormancy

AU - Uhr, Jonathan W.

AU - Pantel, Klaus

PY - 2011/7/26

Y1 - 2011/7/26

N2 - Clinical cancer dormancy is defined as an unusually long time between removal of the primary tumor and subsequent relapse in a patient who has been clinically disease-free. The condition is frequently observed in certain carcinomas (e.g., breast cancer), B-cell lymphoma, and melanoma, with relapse occurring 5-25 y later. Clinical data suggest that a majority of breast cancer survivors have cancer cells for decades but can remain clinically cancer-free for their lifetime. Thus, there is a major effort to characterize the molecular mechanisms responsible for inducing tumor cell dormancy using experimental models or studying the early phases of cancer growth in humans. Many molecules and signaling pathways have been characterized and have led to concepts that dominate the field, such as the possible role of innate and adaptive immunity in immune surveillance and initiation and maintenance of dormancy. However, recent clinical data do not support many of these concepts. Several areas need further study to determine their relevance to clinical cancer dormancy. We suggest hypotheses that may contribute to elucidation of the mechanisms underlying the dormant state.

AB - Clinical cancer dormancy is defined as an unusually long time between removal of the primary tumor and subsequent relapse in a patient who has been clinically disease-free. The condition is frequently observed in certain carcinomas (e.g., breast cancer), B-cell lymphoma, and melanoma, with relapse occurring 5-25 y later. Clinical data suggest that a majority of breast cancer survivors have cancer cells for decades but can remain clinically cancer-free for their lifetime. Thus, there is a major effort to characterize the molecular mechanisms responsible for inducing tumor cell dormancy using experimental models or studying the early phases of cancer growth in humans. Many molecules and signaling pathways have been characterized and have led to concepts that dominate the field, such as the possible role of innate and adaptive immunity in immune surveillance and initiation and maintenance of dormancy. However, recent clinical data do not support many of these concepts. Several areas need further study to determine their relevance to clinical cancer dormancy. We suggest hypotheses that may contribute to elucidation of the mechanisms underlying the dormant state.

KW - Chronic cancer

KW - Circulating tumor cell

KW - Organ size control

UR - http://www.scopus.com/inward/record.url?scp=79961087495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961087495&partnerID=8YFLogxK

U2 - 10.1073/pnas.1106613108

DO - 10.1073/pnas.1106613108

M3 - Article

VL - 108

SP - 12396

EP - 12400

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 30

ER -